Circio Holding ASA — Director's Dealing 2026

Jan 15, 2026

Circio Holding ASA Receipt of subscription rights in the rights issue by primary insiders and their close associates

Circio Holding ASA Receipt of subscription rights in the rights issue by primary insiders and their close associates

Oslo, 15 January 2026: Reference is made to the stock exchange announcement by

Circio Holding ASA (the "Company") earlier today, 15 January 2026, regarding

the commencement of the subscription period for the rights issue (the "Rights

Issue"). As part of this process, subscription rights have been allocated to

primary insiders and their close associates.

Please see the attached notifications of trade for information regarding the

subscription rights received by primary insiders and their close associates in

the Rights Issue.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.